How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,726 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study. (PubMed)

-occupational PEP.We conducted an observational, prospective, multicentre, open-label, non-randomized study in five French HIV centres. Adults requiring PEP according to national French guidelines were prescribed TDF/FTC/RPV one pill once a day for 28 days. Clinical and biological tolerability was assessed at week 4; occurrence of HIV seroconversion was evaluated after week 16.From March 2016 to March 2017, 163 courses of PEP were prescribed for 150 sexual exposures (44% heterosexual and 56% MSM) and 13 non (...) and no serious adverse events or hepatic or renal toxicity occurred. No HIV seroconversion occurred at week 16.The low rate of premature treatment interruption, the good tolerability and the absence of documented HIV seroconversion support the current French guidelines of a 28 day course of TDF/FTC/RPV for sexual and non-sexual PEP.© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email

2019 Journal of Antimicrobial Chemotherapy

142. Efavirenz/Emtricitabine/Tenofovir disoproxil - HIV

Efavirenz/Emtricitabine/Tenofovir disoproxil - HIV 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 14 December 2017 EMA/846772/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Efavirenz/Emtricitabine/Tenofovir disoproxil Krka International non-proprietary name: efavirenz / emtricitabine / tenofovir (...) Environmental Risk Assessment GC-HS Gas Chromatography head space HDPE High Density Polyethylene HIV Human Immunodeficiency Virus HBV Hepatitis B Virus HPLC High performance liquid chromatography ICH International Conference on Harmonisation of Technical Requirements IR Infrared KF Karl Fischer titration LDPE Low Density Polyethylene Ph. Eur. European Pharmacopoeia RMP Risk Management Plan T max Time of maximum observed plasma concentration; if it occurs at more than one time point, Tmax was defined

2018 European Medicines Agency - EPARs

143. Tropical Travel Trouble 009 Humongous HIV Extravaganza

from 2 hours. First line regimen in the UK is Truvada (Tenofovir (TDF) and Emtricitabine (FTC)) and Raltegravir for 28 days with an infectious disease follow up during this time. This regimen was picked due to safety and tolerability over other combinations. If further risk occurs during the last two days of the PEP course, then PEP should be continued for 48 hours after the last high-risk exposure. If more than 48 hours of PEP is missed it should be discontinued. Follow-up HIV testing (...) . Additional Resources Online ID coursesHIV and vaccines – HIV dermatology video: References Beeching N and Gill G. . 7e Wiley Blackwell 2014. BHIVA – – guidelines 2016 BHIVA/BASHH – guidelines on the use of (PrEP) 2017 BHIVA – 2018 BHIVA – 2017 Boer K, et al . Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practice in Western Europe. HIV Med 2010; 11:368-78. Bwakura-Dangarembizi M et al and the Antiretroviral research for Watoto (ARROW) Trial

2018 Life in the Fast Lane Blog

144. Intervene fast to prevent lasting cognitive impairment during the primary phase of HIV infection

primary phase HIV-positive participants (<1 year) over the period from 2005 to 2011. Earlier studies have hypothesized that the neural damage occurs during the phase of primary infection. The researchers seek to establish this by using MRI to examine longitudinal trajectories of brain volume and cortical thickness, and to assess the impact of the introduction of cART. Of the 65 longitudinal participants, 34 had either recently begun cART (4) or did so in the course of the trial. Cross sectional data (...) Intervene fast to prevent lasting cognitive impairment during the primary phase of HIV infection Intervene fast to prevent lasting cognitive impairment during the primary phase of HIV infection | Sexually Transmitted Infections by The impact of HIV/AIDS on cognitive function is the topic of a paper appearing in STIs as early as 1989, where some degree of neurological impairment is observed in patients who otherwise appear ‘well’ ( ). Dementia may be rarely seen nowadays, but quality-of-life

2018 Sexually Transmitted Infections blog

145. The risk network approach to HIV detection: something like contact tracing?

The risk network approach to HIV detection: something like contact tracing? The risk network approach to HIV detection: something like contact tracing? | Sexually Transmitted Infections by There has been considerable debate on the most effective and cost-effective means of accessing untested HIV- or STI-infected individuals. One frequently canvassed strategy is that of respondent driven sampling (RDS). This involves issuing suitable ‘seeds’ (e.g. recently diagnosed MSM) with coupons (...) to distribute to others in their sexual or social networks. in a recent study of black MSM in San Francisco compare RDS very favourably with time location sampling (TLS) as a method of recruitment of those most likely to be at risk. Similary, in a small study in Malawi observe the superior effectiveness of infected, over non-infected seeds in discovering untested individuals (31% vs. 11%). Much, of course, depends on the target group; so, for example, find in favour of ‘venue-based’ sampling over RDS

2018 Sexually Transmitted Infections blog

146. Piloting very early infant diagnosis of HIV in Lesotho: Acceptability and feasibility among mothers, health workers and laboratory personnel. (PubMed)

Piloting very early infant diagnosis of HIV in Lesotho: Acceptability and feasibility among mothers, health workers and laboratory personnel. Mortality associated with in-utero HIV infection rises rapidly within weeks after birth. Very early infant diagnosis of HIV (VEID)-testing within 2 weeks of birth-followed by immediate initiation of antiretroviral therapy has potential to avert mortality associated with in-utero transmission. However, our understanding of acceptability and feasibility (...) of VEID is limited.VEID was piloted in an observational prospective cohort of HIV-positive pregnant women and their infants in 13 Lesotho health facilities. Between March-July 2016, semi-structured interviews were conducted with HIV-positive women attending 6-week or 14-week postnatal visits and health workers (HWs) in 8 study facilities in 3 districts as well as with district and central laboratory staff. Interview themes included acceptability of birth and subsequent HIV testing and early treatment

Full Text available with Trip Pro

2018 PLoS ONE

147. Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rate. (PubMed)

HIV treatment centers participated in this retrospective study. Patients infected with HIV-1 and nonresponding to prior course of vaccination against HBV (anti-HBs <10 IU/ml) and who had Fendrix as a second, third or fourth effort to achieve seroconversion were eligible for inclusion. Primary outcome was the proportion of patients with seroconversion after revaccination with Fendrix. Univariate binary logistic regression analyses were used to determine which factors could be used as predictors (...) Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rate. Patients with HIV have a poor serological conversion rate with the standard vaccination strategy against hepatitis B virus (HBV) of around 50%. Vaccination with Fendrix confers much better results in these patients. In this study, we tested the effect of revaccination with Fendrix in prior nonresponding patients with HIV and aimed to determine which factors are associated with seroconversion.Eight Dutch

2019 AIDS

148. The impact of HIV infection and MSM status on hepatitis A infection: the experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009-2016 period. (PubMed)

(MSM). Some reports described a different clinical course of HAV in patients infected by human immunodeficiency virus (HIV) or MSM.We consecutively collected all the hospitalized cases of hepatitis A referred to two tertiary centres in Northern Italy in 2017 and retrospectively analysed the electronic records of the 2009-2016 period (pre-2017). We evaluated demographics data, risk factors, comorbidities and laboratory results to see if MSM status or HIV infection influenced the disease. Overall 117 (...) > 1.5 at admission. MSM status and HIV infection did not affect neither the clinical course nor the severity of hepatitis A. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.

2019 Journal of viral hepatitis

149. Viral diversity from next-generation sequencing of HIV-1 samples provides precise estimates of infection recency and time since infection. (PubMed)

Viral diversity from next-generation sequencing of HIV-1 samples provides precise estimates of infection recency and time since infection. HIV-1 genetic diversity increases over the course of infection, and can be used to infer time since infection (TSI) and consequently also infection recency, crucial quantities for HIV-1 surveillance and the understanding of viral pathogenesis.We considered 313 HIV-infected individuals for whom reliable estimates of infection dates and next-generation

Full Text available with Trip Pro

2019 Journal of Infectious Diseases

150. Bictegravir / emtricitabine / tenofovir alafenamide / fumarate (Biktarvy) - HIV Infections

exposure is low; estimates are on the order of 0.1% per contact for heterosexual transmission, but this varies considerably and increases with concurrent ulcerative STDs, high HIV viral load in the subject, and lack of antiretroviral therapy. 2.1.2. Epidemiology There are approximately 37 million people worldwide living with HIV-1. HIV-1 infection remains a life- threatening disease in infected persons who do not receive adequate treatment sufficiently early in the course of the infection (...) Bictegravir / emtricitabine / tenofovir alafenamide / fumarate (Biktarvy) - HIV Infections 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 26 April 2018 EMA/293559/2018 Committee for Medicinal Products for Human Use (CHMP

2018 European Medicines Agency - EPARs

151. The risk network approach to HIV detection: something like contact tracing?

The risk network approach to HIV detection: something like contact tracing? The risk network approach to HIV detection: something like contact tracing? | Sexually Transmitted Infections by There has been considerable debate on the most effective and cost-effective means of accessing untested HIV- or STI-infected individuals. One frequently canvassed strategy is that of respondent driven sampling (RDS). This involves issuing suitable ‘seeds’ (e.g. recently diagnosed MSM) with coupons (...) to distribute to others in their sexual or social networks. in a recent study of black MSM in San Francisco compare RDS very favourably with time location sampling (TLS) as a method of recruitment of those most likely to be at risk. Similary, in a small study in Malawi observe the superior effectiveness of infected, over non-infected seeds in discovering untested individuals (31% vs. 11%). Much, of course, depends on the target group; so, for example, find in favour of ‘venue-based’ sampling over RDS

2018 Sexually Transmitted Infections blog

152. Metabolic syndrome and endocrine status in HIV-infected transwomen. (PubMed)

Metabolic syndrome and endocrine status in HIV-infected transwomen. HIV-infected transwomen face multiple specific issues. Economic and social marginalization, sex work, substance abuse, hormonal consumption and silicone injection may affect the course of HIV infection and lead to metabolic and endocrine complications.A matched case-control study was performed between 2013 and 2015 in a University Hospital and compared metabolic syndrome, thyroid and adrenal functions in HIV-infected transwomen (...) (i.e.; cases) and cisgender HIV-infected men (i.e.; controls) matched for age and antiretroviral therapy. The interaction between hormonal consumption, the course of HIV infection and antiretroviral therapy was also studied. Clinical and biological data (CD4 cell count, HIV RNA load, antiretroviral plasma drug concentration, HDL, triglycerides, glucose, cortisol, TSH, FT4, prolactine) were measured.292 HIV-infected patients (100 cases and 192 controls) were prospectively included

2019 AIDS

153. Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol. (PubMed)

. Importantly, the size of the HIV reservoir is larger in individuals who start ART late in the course of infection and have a low CD4+/CD8+ ratio. HIV reservoir size is also linked to the levels of persistent inflammation on ART. Thus, novel strategies to reduce immune inflammation and improve the host response to control the HIV reservoir would be a valuable addition to current ART. Among the different strategies under investigation is metformin, a widely used antidiabetic drug that was recently shown (...) Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol. People living with HIV (PLWH) on antiretroviral therapy (ART) do not progress to AIDS. However, they still suffer from an increased risk of inflammation-associated complications. HIV persists in long-lived CD4+ T cells, which form the major viral reservoir. The persistence of this reservoir despite long-term ART is the major hurdle to curing HIV

Full Text available with Trip Pro

2019 BMJ open

154. A Mixed Methods Evaluation of an Inclusive Sexual History Taking and HIV Prevention Curriculum for Trainees. (PubMed)

, sexually transmitted infections, and HIV risk assessment and risk reduction counseling including use of PrEP.A dedicated PrEP Clinic was created within an Academic Medical Center Outpatient HIV Clinic. Patients were primarily LGBTQ identified, but also included HIV sero-discordant couples, cisgender individuals, heterosexual invididuals, and those with experience of homelessness, sex work, and substance abuse.Thirty-four internal medicine residents completed the course between November 2017 and May (...) statistically significant increased confidence and comfort in all seven HIV prevention topic areas, with the greatest gains in safe sex counseling for LGBTQ patients and in discussing PrEP (mean changes of 1.21, 1.58 on 5-point Likert scale, respectively, p < 0.0001). Six of nine interviewees post-course had applied what they learned to patient care; five indicated their learning would benefit patients.An HIV prevention curriculum focused on cultural humility in care can improve trainee's skills in HIV risk

2019 Journal of General Internal Medicine

155. Updates on HIV nonoccupational postexposure prophylaxis. (PubMed)

to increase provider awareness of appropriate nPEP prescription.Research of HIV nPEP shows that it is effective when used correctly, but there needs to be increased education and awareness to increase provider prescription and patient use as well as institutional changes to help patients complete the full course of medication. (...) Updates on HIV nonoccupational postexposure prophylaxis. Adolescents and young adults continue to contribute to new HIV infections despite improved antiretroviral regimens and HIV preexposure and postexposure prophylaxis (PrEP and PEP). Knowledge about nonoccupational HIV PEP (nPEP) is relevant and important for all pediatricians as adolescents present under a variety of circumstances disclosing past sexual activity.nPEP is effective in preventing HIV infection, and newer regimens have been

2019 Current Opinion in Pediatrics

156. Baseline characteristics of HIV & hepatitis B virus (HIV/HBV) co-infected patients from Kolkata, India (PubMed)

Baseline characteristics of HIV & hepatitis B virus (HIV/HBV) co-infected patients from Kolkata, India Hepatitis B virus (HBV) and HIV co-infection has variable prevalence worldwide. In comparison to HBV mono-infection, the course of chronic HBV infection is accelerated in HIV/HBV co-infected patients. the present study was carried out to analyse the baseline characteristics (clinical, biochemical, serological and virological) of treatment naïve HIV/HBV co-infected and HIV mono-infected (...) patients.Between July 2011 and January 2013, a total number of 1331 HIV-seropositive treatment naïve individuals, enrolled in the ART Centre of Calcutta School of Tropical Medicine, Kolkata, India, were screened for hepatitis B surface antigen (HBsAg). A total of 1253 HIV mono-infected and 78 HIV/HBV co-infected patients were characterized. The co-infected patients were evaluated for HBeAg and anti-HBe antibody by ELISA. HIV RNA was quantified for all co-infected patients. HBV DNA was detected and quantified

Full Text available with Trip Pro

2016 The Indian journal of medical research

157. HIV Disclosure and Transmission Risks to Sex Partners Among HIV-Positive Men (PubMed)

with uninfected sex partners. Sexually active HIV-positive men (N = 538) completed daily electronic sexual behavior assessments over the course of 28 days and completed computerized interviews, drug testing, medication adherence assessments, and HIV viral load retrieved from medical records. Results showed that 166 (30%) men had engaged in condomless vaginal or anal intercourse with an HIV-uninfected or unknown HIV status sex partner to whom they had not disclosed their HIV status. Men who engaged (...) HIV Disclosure and Transmission Risks to Sex Partners Among HIV-Positive Men Disclosure of HIV-positive status to sex partners is critical to protecting uninfected partners. In addition, people living with HIV often risk criminal prosecution when they do not inform sex partners of their HIV status. The current study examined factors associated with nondisclosure of HIV status by men living with HIV in Atlanta, GA (92% African African, mean age = 43.8), who engage in condomless sex

Full Text available with Trip Pro

2016 AIDS patient care and STDs

158. Study to Evaluate the Safety and Immunogenicity of Orally-administered HIV Vaccine in Healthy, HIV-uninfected Adult Participants

Study to Evaluate the Safety and Immunogenicity of Orally-administered HIV Vaccine in Healthy, HIV-uninfected Adult Participants Study to Evaluate the Safety and Immunogenicity of Orally-administered HIV Vaccine in Healthy, HIV-uninfected Adult Participants - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study to Evaluate the Safety and Immunogenicity of Orally-administered HIV Vaccine in Healthy, HIV-uninfected Adult Participants The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02771730 Recruitment

2016 Clinical Trials

159. Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults The safety and scientific validity of this study is the responsibility of the study sponsor

2016 Clinical Trials

160. A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plu

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plu A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade (...) C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>